Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • January 25, 2021 9:11 AM | Becca Liebers (Administrator)

    APAOG is now accepting partner applications for our women's health resource center. If you want to increase your exposure to PAs who practice in women's health, this opportunity is for you. Our premium and supporting partner options provide a range of benefits at great prices. Contact our office with any questions.

    Visit our Partners webpage for more information about this opportunity!

  • January 23, 2021 9:09 AM | Becca Liebers (Administrator)

    Today is #MaternalHealthAwarenessDay and APAOG is observing with our fellow women’s health professionals in order to improve maternal health outcomes and eliminate inequities for our patients and for moms across the country. #123ForMoms #PAs #OBGYN #WomensHealth #APAOG #ACOG 

  • January 04, 2021 9:56 AM | Becca Liebers (Administrator)

    Walk Through Steps of Administering LARC in CME
    Nisha McKenzie, PA-C, CSC, NCMP, IF and Deanna Bridge Najera, PA-C

    Nisha McKenzie, PA-C, CSC, NCMP, IF, founder of Women’s Health Collective in Grand Rapids, Michigan, and Deanna Bridge Najera, PA-C, clinician consultant in Carroll County, Maryland, team up to talk about Long-Acting Reversible Contraception (LARC). They are also the featured instructors in LARC CME available now on AAPA’s Learning Central. The CME covers how LARC use comes up and is discussed in real interactions with patients. It includes real-life scenarios often lacking in training but are quite helpful for clinical practice. Here, McKenzie and Najera share tips on LARC and treating patients.

    Read more.

  • December 16, 2020 10:04 AM | Becca Liebers (Administrator)

    “As an OBGYN PA for over 10 years, I have had the privilege to work in a field that I am passionate about. Being a PA has allowed me to transition between labor and delivery, high risk obstetrics, gynecology, minimally invasive surgery, and outpatient settings. We are primary care, medical, and surgical subspecialties in one. APAOG has provided in-depth webinars of necessary topics and connections with successful PAs in the field. Without these benefits it would have been challenging to progress in OBGYN. Now, with a thorough understanding of the opportunities and barriers to PAs in women's health, we have come together to offer even more for our members. We are looking forward to a larger community of like-minded PAs to improve our presence in obstetrics and gynecology.”
    - Melissa Rodriguez, PA-C

  • December 14, 2020 8:01 AM | Becca Liebers (Administrator)

    ACOG | Published December 13, 2020

    This Practice Advisory was developed by the American College of Obstetricians and Gynecologists’ Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group in collaboration with Laura E. Riley, MD; Richard Beigi, MD; Denise J. Jamieson, MD, MPH; Brenna L. Hughes, MD, MSc; Geeta Swamy, MD; Linda O’Neal Eckert, MD; Cynthia Gyamfi-Bannerman, MD, MSc; and Mark Turrentine, MD.

    Summary of Key Information and Recommendations 

    COVID-19 vaccine development and regulatory approval are rapidly progressing. Thus, information and recommendations will evolve as more data are collected about these vaccines and their use in specific populations. This Practice Advisory is intended to be an overview of currently available COVID-19 vaccines and guidance for their use in pregnant and lactating patients.

    • On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNtech mRNA vaccine (BNT162b2) for use in individuals age 16 years and older as a 2-dose regimen given 3 weeks apart. This vaccine has shown to be 95% effectivat preventing COVID-19 illness after the second dose.
    • On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19 illness. 
    • ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups. 
    • COVID-19 vaccines should be offered to lactating individuals similar to non-lactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by the ACIP.
    • Individuals considering a COVID-19 vaccine should have access to available information about the safety and efficacy of the vaccine, including information about data that are not available. A conversation between the patient and their clinical team may assist with decisions regarding the use of vaccines approved under EUA for the prevention of COVID-19 by pregnant patients.  Important considerations include:
      • the level of activity of the virus in the community 
      • the potential efficacy of the vaccine
      • the risk and potential severity of maternal disease, including the effects of disease on the fetus and newborn 
      • the safety of the vaccine for the pregnant patient and the fetus.
    • While a conversation with a clinician may be helpful, it should not be required prior to vaccination, as this may cause unnecessary barriers to access.
    • Vaccines currently available under EUA have not been tested in pregnant women. Therefore, there are no safety data specific to use in pregnancy. See details about the Food and Drug Administration’s (FDA) EUA process below.
    • Pregnancy testing should not be a requirement prior to receiving Pfizer-BioNTech vaccine. 
    • Pregnant patients who decline vaccination should be supported in their decision. Regardless of their decision to receive or not receive the vaccine, these conversations provide an opportunity to remind patients about the importance of other prevention measures such as hand washing, physical distancing, and wearing a mask. 
    • Expected side effects should be explained as part of counseling patients, including that they are a normal part of the body’s reaction to the vaccine and developing antibodies to protect against COVID-19 illness.
    • The mRNA vaccines are not live virus vaccines, nor do they use an adjuvant to enhance vaccine efficacy. These vaccines do not enter the nucleus and do not alter human DNA in vaccine recipients. As a result, mRNA vaccines cannot cause any genetic changes.

    Read more.

  • December 09, 2020 10:02 AM | Becca Liebers (Administrator)

    "Nationwide a small percent of PAs specialize in Obstetrics & Gynecology, therefore, being part of an Ob/Gyn PA network is invaluable. APAOG not only offers networking opportunities, but also monthly newsletters with up-to-date content, and quarterly webinars for CME credit to members. As a member of APAOG I have been able to enhance my learning and education within women's health as well as become informed on guidelines and new practices."
    Melanie A. Jacobs, MMS, PA-C

  • December 07, 2020 8:58 AM | Becca Liebers (Administrator)

    CNN | LaMotte

    The stress a woman feels during pregnancy can affect the developing brain of her unborn child as documented on fetal brain scans, according to a new study published Monday in the medical journal JAMA Open Network.

    Fetuses of expectant moms with higher anxiety levels were more likely to have weaker connections between two brain areas involved in executive and higher cognitive functions and stronger connections between parts of the brain connected to emotional and behavioral controls.

    The study echoes other recent research that has found a direct impact of maternal stress on a baby's future development.

    Read more.

  • December 01, 2020 3:09 PM | Becca Liebers (Administrator)

    Report & CME Now Available to Members

    WPP and AAPA presented the final report of the Physician Assistant Title Change Investigation to the AAPA House of Delegates and AAPA members virtually on November 20. The recorded presentation is now available free to AAPA members for CME credit in Learning Central. Members can also access a PDF of the Title Change Investigation Final Report by logging in to AAPA’s website.

    Click here for more information on the PA Title Change Investigation.

  • November 10, 2020 10:50 AM | Becca Liebers (Administrator)

    Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate | STAT

    Pfizer and partner BioNTech said Monday that their vaccine against Covid-19 was strongly effective, exceeding expectations with results that are likely to be met with cautious excitement — and relief — in the face of the global pandemic.

    The vaccine is the first to be tested in the United States to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic Covid-19 than those who received a placebo. For months, researchers have cautioned that a vaccine that might only be 60% or 70% effective. 

    The Phase 3 study is ongoing and additional data could affect results.

    Read more.

  • September 30, 2020 7:48 AM | Becca Liebers (Administrator)

    Journal of the American Academy of Physician Assistants | Paluch, Lauren DMSc, MPA, PA-C

    Bronchiolitis is a common viral illness that affects the lower respiratory tract of infants and young children. The disease is characterized by wheezing and increased mucus production and can range from mild to severe in terms of respiratory distress. This article reviews the epidemiology, clinical presentation, and treatment of bronchiolitis.

    Read more.

Powered by Wild Apricot Membership Software